Skip to main content
Celltrion, Inc. logo

Celltrion, Inc. — Investor Relations & Filings

Ticker · 068270 ISIN · KR7068270008 LEI · 988400JFZG785WJX3D68 KO Manufacturing
Open in API
Filings indexed 1,282 across all filing types
Latest filing 2026-03-18 Major Shareholding Noti…
Country KR South Korea
Listing KO 068270

About Celltrion, Inc.

https://www.celltrion.com/

Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status of the company's largest shareholder (Celltrion Holdings) and its special related parties, including changes in ownership and the purpose of holding (management influence). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2026-03-18 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Celltrion regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details a pharmaceutical contract manufacturing agreement, including contract value, duration, and counterparty information. Since this is a specific regulatory disclosure of a material business contract that does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2026-03-17 Korean
감사보고서제출
Audit Report / Information Classification · 99% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by Celltrion. It provides the auditor's opinion (unqualified/appropriate), key financial data (assets, liabilities, revenue, profit), and details regarding the audit firm (Samil PwC). While it contains financial data, it is a regulatory filing announcing the submission of the audit report to the exchange (KRX), which is a standard procedure for annual financial reporting in Korea. Given the structure and the specific regulatory nature of the filing, it falls under the Audit Report/Information category. FY 2025
2026-03-16 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 98% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Celltrion, including the independent auditor's opinion, consolidated financial statements (balance sheet, income statement, cash flow, etc.), and detailed notes. It is not an Annual Report (10-K) as it focuses specifically on the audit and financial statements rather than the full narrative business report, and it is not an announcement (RPA) because it contains the full financial data and audit findings. FY 2025
2026-03-16 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a formal regulatory filing in South Korea used by shareholders or third parties to solicit proxies from other shareholders for an upcoming General Meeting. This falls under the category of Proxy Solicitation & Information Statement (PSI).
2026-03-12 Korean
투자판단관련주요경영사항 (CTP55(코센틱스 바이오시밀러) 미국 임상 3상 시험계획 변경신청)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Celltrion regarding a change in their Phase 3 clinical trial application for CT-P55 (a biosimilar) submitted to the US FDA. It is a formal disclosure of a material business event ('투자판단 관련 주요경영사항'). Since it does not fit into specific categories like financial reports, dividends, or director dealings, and is a standard regulatory disclosure of a clinical trial update, it falls under the 'Regulatory Filings' category.
2026-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.